Pharma BD Deal Intelligence
A rare win-win swap: BI built a top-2 global animal health franchise from Merial, while Sanofi's consumer health business (later Opella) grew into a €16B standalone leader — both sides monetized their focus-area bets.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
FiercePharma's coverage of the exclusive-negotiations announcement highlighted the strategic clarity of trading non-core franchises rather than divesting at…
Bloomberg framed the EUR 22.8B swap as a model transaction in which both parties traded subscale franchises for category leadership without taking on net…
The FTC required limited divestitures as a condition of the $13.53B BI-Sanofi animal-health leg, signaling regulators viewed remaining competition (Zoetis,…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi and Boehringer Ingelheim signed definitive agreements for a EUR 22.8B (~$25.1B) business swap: BI acquired Sanofi's Merial animal health business (EV EUR 11.4B / ~$13.5B) and Sanofi acquired BI's consumer healthcare business (EV EUR 6.7B / ~$8.0B) plus EUR 4.7B (~$5.5B) cash. Closed in most markets January 1, 2017. Strategic intent: Sanofi to lead in OTC consumer health, BI to become #2 in animal health.
A rare win-win swap: BI built a top-2 global animal health franchise from Merial, while Sanofi's consumer health business (later Opella) grew into a €16B standalone leader — both sides monetized their focus-area bets.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi S.A. / Boehringer Ingelheim GmbH (consumer healthcare business swap) (this deal) | 2016 | $25.1B | 84 |
| Sanofi S.A. / Vicebio Ltd. | 2025 | $1.6B | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2016 deals · Other deals